CN114127117B - 用于偶联的多肽复合物及其应用 - Google Patents

用于偶联的多肽复合物及其应用 Download PDF

Info

Publication number
CN114127117B
CN114127117B CN202080051466.8A CN202080051466A CN114127117B CN 114127117 B CN114127117 B CN 114127117B CN 202080051466 A CN202080051466 A CN 202080051466A CN 114127117 B CN114127117 B CN 114127117B
Authority
CN
China
Prior art keywords
ser
pro
val
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080051466.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114127117A (zh
Inventor
金明志
陈晓悦
张玥
张晨
阴丽
蔡洁行
王俊
周伟昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yaoming Helian Biotechnology Co ltd
Original Assignee
Shanghai Yaoming Helian Biotechnology Co ltd
Wuxi Biologics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yaoming Helian Biotechnology Co ltd, Wuxi Biologics Shanghai Co Ltd filed Critical Shanghai Yaoming Helian Biotechnology Co ltd
Publication of CN114127117A publication Critical patent/CN114127117A/zh
Application granted granted Critical
Publication of CN114127117B publication Critical patent/CN114127117B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080051466.8A 2019-07-19 2020-07-17 用于偶联的多肽复合物及其应用 Active CN114127117B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/096849 2019-07-19
CN2019096849 2019-07-19
PCT/CN2020/102585 WO2021013068A1 (en) 2019-07-19 2020-07-17 Polypeptide complex for conjugation and use thereof

Publications (2)

Publication Number Publication Date
CN114127117A CN114127117A (zh) 2022-03-01
CN114127117B true CN114127117B (zh) 2024-03-15

Family

ID=74193121

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080051466.8A Active CN114127117B (zh) 2019-07-19 2020-07-17 用于偶联的多肽复合物及其应用

Country Status (9)

Country Link
US (1) US20220267467A1 (https=)
EP (1) EP3999544A4 (https=)
JP (1) JP7455188B2 (https=)
KR (1) KR102949500B1 (https=)
CN (1) CN114127117B (https=)
AU (1) AU2020318112C1 (https=)
CA (1) CA3147690A1 (https=)
TW (1) TWI845724B (https=)
WO (1) WO2021013068A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022014698A1 (https=) * 2020-07-17 2022-01-20
CN118480117B (zh) * 2021-01-18 2025-03-04 上海药明合联生物技术有限公司 工程化抗体和包含工程化抗体的抗体-药物偶联物
CN116981695A (zh) * 2022-05-06 2023-10-31 上海药明合联生物技术有限公司 含工程化铰链区的抗体及其应用
TW202411249A (zh) * 2022-05-20 2024-03-16 大陸商上海邁晉生物醫藥科技有限公司 抗體－藥物偶聯物的製備方法
CN115947830B (zh) * 2022-12-27 2023-09-12 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
WO2026011391A1 (en) * 2024-07-11 2026-01-15 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anti-cd276 antibody, antibody-drug conjugate, and use thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103003307A (zh) * 2010-03-10 2013-03-27 根马布股份公司 抗c-MEt的单克隆抗体
WO2013096346A1 (en) * 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
CN106892982A (zh) * 2017-04-05 2017-06-27 东北农业大学 靶向IL‑17和TNFα的新型融合多肽及其应用
CN107207579A (zh) * 2015-03-31 2017-09-26 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
CN107849102A (zh) * 2015-05-15 2018-03-27 希望之城 嵌合抗原受体组合物
CN108884170A (zh) * 2016-03-22 2018-11-23 豪夫迈·罗氏有限公司 蛋白酶活化的t细胞双特异性分子
CN109536450A (zh) * 2018-11-02 2019-03-29 北京贝来生物科技有限公司 一种阻断Th17信号通路治疗自身免疫病的间充质干细胞及其制备方法和应用
CN109535257A (zh) * 2017-09-22 2019-03-29 上海药明生物技术有限公司 新型双特异性cd3/cd19多肽复合物
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172731A (zh) * 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
MX2009012343A (es) * 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
CA2777242A1 (en) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
US10669328B2 (en) * 2013-11-12 2020-06-02 Ogd2 Pharma Human IgG1 derived antibody with pro-apoptotic activity
PL3212226T3 (pl) * 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
BR112018010172A2 (pt) * 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
GB201612520D0 (en) * 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN110177569A (zh) * 2017-03-30 2019-08-27 江苏恒瑞医药股份有限公司 抗体药物偶联物的制备方法
CN111032085A (zh) * 2017-06-05 2020-04-17 昆士兰医学研究所理事会 用于癌症治疗或预防的免疫检查点分子拮抗剂和rank-l（nf-kb配体）拮抗剂的组合或其双特异性结合分子及其用途
EP3634485A4 (en) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
CA3101019A1 (en) * 2018-06-01 2019-12-05 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
CN109628406B (zh) * 2019-01-03 2021-02-26 北京贝来生物科技有限公司 一种治疗自身免疫疾病的间充质干细胞及其制备方法和应用

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103003307A (zh) * 2010-03-10 2013-03-27 根马布股份公司 抗c-MEt的单克隆抗体
WO2013096346A1 (en) * 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
CN104144949A (zh) * 2011-12-22 2014-11-12 财团法人生物技术开发中心 双特异性t细胞活化剂抗体
CN107207579A (zh) * 2015-03-31 2017-09-26 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
CN107849102A (zh) * 2015-05-15 2018-03-27 希望之城 嵌合抗原受体组合物
CN108884170A (zh) * 2016-03-22 2018-11-23 豪夫迈·罗氏有限公司 蛋白酶活化的t细胞双特异性分子
CN106892982A (zh) * 2017-04-05 2017-06-27 东北农业大学 靶向IL‑17和TNFα的新型融合多肽及其应用
CN109535257A (zh) * 2017-09-22 2019-03-29 上海药明生物技术有限公司 新型双特异性cd3/cd19多肽复合物
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
CN109536450A (zh) * 2018-11-02 2019-03-29 北京贝来生物科技有限公司 一种阻断Th17信号通路治疗自身免疫病的间充质干细胞及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity;S. Giuntini等;《Clinical and Vaccine Immunology》;第23卷(第8期);第698-706页 *
LC-MS 法对抗PD-1 信迪利单抗药物分子 铰链区序列改构稳定性的研究;于传飞等;《药学学报》;第54卷(第1期);第122-129页 *

Also Published As

Publication number Publication date
WO2021013068A1 (en) 2021-01-28
AU2020318112C1 (en) 2024-09-26
EP3999544A4 (en) 2023-08-09
TWI845724B (zh) 2024-06-21
JP7455188B2 (ja) 2024-03-25
CA3147690A1 (en) 2021-01-28
JP2022540946A (ja) 2022-09-20
AU2020318112B2 (en) 2024-09-05
EP3999544A1 (en) 2022-05-25
KR102949500B1 (ko) 2026-04-09
KR20220041851A (ko) 2022-04-01
US20220267467A1 (en) 2022-08-25
AU2020318112A1 (en) 2022-02-24
TW202116808A (zh) 2021-05-01
CN114127117A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
JP7553504B2 (ja) 操作された抗体化合物およびこれらの抱合体
CN114127117B (zh) 用于偶联的多肽复合物及其应用
TWI865842B (zh) 蛋白-藥物偶聯物和定點偶聯方法
JP6770535B2 (ja) Ｃｄ１２３抗体及びその複合体
WO2022152289A1 (en) An engineered antibody and antibody-drug conjugates comprisign same
US10112999B2 (en) Anti-PRLR antibody-drug conjugates (ADC) and uses thereof
CN116761824B (zh) 工程化抗-trop2抗体及其抗体-药物偶联物
WO2021219046A1 (zh) 靶向her2的抗原结合构建体及用途
EP4725968A1 (en) Anti-gpc3 antibody or antigen-binding fragment and use thereof
CN116981695A (zh) 含工程化铰链区的抗体及其应用
JP2025542294A (ja) Ａｌｐｐ特異的バリアント抗原結合分子
WO2025261511A1 (zh) 靶向cdh17的抗体和adc及其应用
TW202547884A (zh) Ｍｕｃ１６／ｎａｐｉ－２ｂ抗體及使用方法
WO2024223835A1 (en) Binding molceule against p95 her2 variants
WO2024002258A1 (zh) 抗体可变区的突变体及其应用
HK40047122B (en) Protein-drug conjugate and site-specific conjugating method
HK40047122A (en) Protein-drug conjugate and site-specific conjugating method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230512

Address after: 200131 Pudong New Area, Shanghai, China (Shanghai) free trade pilot area, 211 North 302, 368 room.

Applicant after: Shanghai Yaoming Helian Biotechnology Co.,Ltd.

Address before: No. 299, Fute Middle Road, Pudong New Area, Shanghai 200131

Applicant before: WUXI BIOLOGICS (SHANGHAI) Co.,Ltd.

GR01 Patent grant
GR01 Patent grant